Sun, Apr 20, 2014, 10:58 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

stemcellmagnet 28 posts  |  Last Activity: Apr 16, 2014 6:13 AM Member since: Jul 26, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • "Osiris is getting ready for tighter price controls at sometime in the future, by developing some smaller Grafix sizes and releasing them sometime in the 2nd quarter. 2014. Make no mistake about it Osiris will compete."

    There are already multitudes of complaints from people who have tried the current and smallest size of Grafix and the handling characteristics are reported to be terrible and almost impossible to use.

    Sentiment: Strong Buy

  • stemcellmagnet by stemcellmagnet Mar 11, 2014 11:44 AM Flag

    The key elements needed to push a product through the Medicare hoops to get reimbursement approval are
    "1) An FDA sanctioned product, 2) a product that is efficacious in its purpose, 3) manufactured in an FDA approved facility, 4)proof of efficacy demonstrated by scientific trials, 5) peer reviews, white papers and publication in an accepted scientific journal."

    1. NEITHER GRAFFIX OR OVATION IS A FDA SANCTIONED PRODUCT! THE FDA DOESN"T SANCTION PRODUCT. THE FDA CLASSIFIES AS ONE OF HCTP OR 510K or PMA PRODUCT, DRUG, OR THE LIKE.
    2. AGREED
    3. FDA DOES NOT APPROVE A TISSUE FACILITIES OR MED DEVICE FACILITIES THEY AUDIT OR INSPECT THEM, BUT THEY DO NOT APPROVE ANY FACILITIES FOR TISSUE OR DEVICES.
    4. AGREED
    5. OSIRIS DOES NOT CURRENTLY HAVE ANY PEER REVIEWED PUBLISHED CLINICAL STUDIES ON GRAFIX. (MIMEDX HAS 3 PLUS A PUBLISHED CROSSOVER STUDY AND A LONG TERM WOUND RECURRENCE STUDY) MANY MACS WILL REQUIRE MORE THAN ONE PEER REVIEWED PUBLISHED STUDY

    Sentiment: Strong Sell

  • stemcellmagnet by stemcellmagnet Mar 11, 2014 11:27 AM Flag

    The key elements needed to push a product through the Medicare hoops to get reimbursement approval are
    "1) An FDA sanctioned product, 2) a product that is efficacious in its purpose, 3) manufactured in an FDA approved facility, 4)proof of efficacy demonstrated by scientific trials, 5) peer reviews, white papers and publication in an accepted scientific journal."

    1. NEITHER GRAFFIX OR OVATION IS A FDA SANCTIONED PRODUCT! THE FDA DOESN"T SANCTION PRODUCT. THE FDA CLASSIFIES AS ONE OF HCTP OR 510K or PMA PRODUCT, DRUG, OR THE LIKE.
    2. AGREED
    3. FDA DOES NOT APPROVE A TISSUE FACILITIES OR MED DEVICE FACILITIES THEY AUDIT OR INSPECT THEM, BUT THEY DO NOT APPROVE ANY FACILITIES FOR TISSUE OR DEVICES.
    4. AGREED
    5. OSIRIS DOES NOT CURRENTLY HAVE ANY PEER REVIEWED PUBLISHED CLINICAL STUDIES ON GRAFIX. (MIMEDX HAS 3 PLUS A PUBLISHED CROSSOVER STUDY AND A LONG TERM WOUND RECURRENCE STUDY) MANY MACS WILL REQUIRE MORE THAN ONE PEER REVIEWED PUBLISHED STUDY

    Sentiment: Strong Buy

  • The leader in this sector of healthcare, Mimedx who is growing faster than Osiris, has a market cap of revenue of less than 7x on 2014 estimated Revenues. The reason for this is that the Mimedx shareholders are large institutional investors who understand how to value corporations. Mimedx has not participated in all the "HYPE"
    If you want to pay three times for a stock in a similar area of healthcare than what the leadership company is selling for then go right ahead. However that is an investment thesis that is idiocy.
    While both of these companies have some exciting products, the clinical attributes of the Mimedx product demonstrated itself through a series of clinical and scientific publications in peer reviewed journals. This is the reason that Mimedx has obtained approval of 7 of 8 Medicare intermediaries during 2013 and Osiris has gotten NONE!!!! BIG DIFFERENCE!
    ONE ANALYSTS THAT COVERS OSIRIS HAS JUST PROJECTED A LOSS FOR 2014! THIS IS BECAUSE THAY HAVE HIRED TO MANYS SALES PEOPLE AT A TIME WHEN THEIR PRODUCT DOES NOT EVEN HAVE MEDICARE APPROVAL ANYWHERE IN THE COUNTRY!!!
    The article"Osiris Therapeutics:" Poised for another break out" isFULL OF INCORRECT STATEMENTS AND MISINFORMATION!!!! Mimedx's revenues for 2013 were over THREE TIMES those of OSIRIS Not 3 Million more. HUGE MISTAKE!!!!
    IF YOU ARE A SAVY INVESTOR WHO BELIEVES THE FINANCIALS ARE WHAT DRIVES STOCK PRICES

    Sentiment: Strong Sell

  • The leader in this sector of healthcare, Mimedx who is growing faster than Osiris, has a market cap of revenue of less than 7x on 2014 estimated Revenues. The reason for this is that the Mimedx shareholders are large institutional investors who understand how to value corporations. Mimedx has not participated in all the "HYPE"
    If you want to pay three times for a stock in a similar area of healthcare than what the leadership company is selling for then go right ahead. However that is an investment thesis that is idiocy.
    While both of these companies have some exciting products, the clinical attributes of the Mimedx product demonstrated itself through a series of clinical and scientific publications in peer reviewed journals. This is the reason that Mimedx has obtained approval of 7 of 8 Medicare intermediaries during 2013 and Osiris has gotten NONE!!!! BIG DIFFERENCE!
    ONE ANALYSTS THAT COVERS OSIRIS HAS JUST PROJECTED A LOSS FOR 2014! THIS IS BECAUSE THAY HAVE HIRED TO MANYS SALES PEOPLE AT A TIME WHEN THEIR PRODUCT DOES NOT EVEN HAVE MEDICARE APPROVAL ANYWHERE IN THE COUNTRY!!!
    The article"Osiris Therapeutics:" Poised for another break out" isFULL OF INCORRECT STATEMENTS AND MISINFORMATION!!!! Mimedx's revenues for 2013 were over THREE TIMES those of OSIRIS Not 3 Million more. HUGE MISTAKE!!!!
    IF YOU ARE A SAVY INVESTOR WHO BELIEVES THE FINANCIALS ARE WHAT DRIVES STOCK PRICES

    Sentiment: Strong Buy

  • https://www.youtube.com/watch?v=t_jAV0zmmvQ

    Sentiment: Strong Buy

  • Bill Taylor just filed adding to his Position.

    Sentiment: Strong Buy

  • As per Kalorma Information, the global market for wound care products is projected to grow from $16.8B in 2012, to approximately $21B by 2015 (a CAGR of 7.7%). Demand is rising due to an aging population, higher rates of obesity and longer life expectancies. The market for tissue based wound care products is estimated to be $400 million, with Shire's (SHPG) Dermagraft and Organogenesis' Apligraf accounting for about 60% of sales in the category. However, there is an ongoing shift toward the fast-growing regenerative wound care treatments. MiMedx's (MDXG) amniotic membrane products are seeing triple-digit demand growth as they continue to seize market share from legacy products. Giant pharma Celgene (CELG) will also target this emerging segment of the wound care market through their Alliqua (OTCQB:ALQA) extension. The advantage of natural tissue-based collagen and wound healing factors contained in placenta based treatments will leave two major players in the segment as others will be crowded out.

    Sentiment: Strong Buy

MDXG
5.71-0.06(-1.04%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.